Barrett, Sonsalla, and Hines
Elected to ASPET Leadership

In the recent election, ASPET members elected James E. Barrett as President-Elect, Patricia K. Sonsalla as Secretary/Treasurer-Elect, and Ronald N. Hines as Councilor.

James E. Barrett, President of Research and Development at Memory Pharmaceuticals Corporation in Montvale, New Jersey, will assume the responsibilities of President-Elect in July 2004. Dr. Barrett is past Secretary/Treasurer of ASPET.

Patricia K. Sonsalla, Professor in the Department of Neurology and Associate Professor in the Departments of Pharmacology and Psychiatry at the University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, will become Secretary/Treasurer-Elect in July 2004. She is currently a Councilor and is a past chair of the Division for Neuropharmacology.

Ronald N. Hines will assume the position of Councilor in July. Dr. Hines is Professor of Pediatrics and Pharmacology/Toxicology at the Medical College of Wisconsin and Co-Director of the Birth Defects Research Center and Co-Section Chief of Clinical Pharmacology, Pharmacology and Teratology at Children’s Hospital of Wisconsin and Medical College of Wisconsin. He is a past chair of the Division for Drug Metabolism.

Inside this Issue

- Award Winners for 2004
- Division Election Results
- Public Affairs Programming for EB ‘04
- Call for Award
The Pharmacologist

News
Election 2004 Results ........................................ page 1
Award Winners for 2004 ........................................ page 3
EB ’04 Program Highlights .......................... page 9
Public Affairs Programming at EB ’04 ............ page 14

Features
Journals ........................................................... page 17
Public Affairs & Government Relations ........... page 18
Division News .................................................... page 19
Division Election Results .......................... page 19
B.B. Brodie Award Fund Progress Report .......... page 20
Members in the News ....................................... page 20
Staff News ....................................................... page 22
New Members ................................................ page 23
2004 Contributors ........................................ page 24
Obituaries ....................................................... page 25
Death Notices ................................................... page 26

Announcements
Call for 2005 Award Nominations ................ page 6
2nd RGS Proteins Colloquium ............................... page 12
Instructions for Oral Presentations – EB ’04 .... page 13
Pharmacotherapy of Obesity ......................... page 16
NC-IUPHAR Web Sites Available ...................... page 28
Purines 2004 ................................................ page 30
CPT 2004 ......................................................... page 31
FASEB Summer Research Conferences ........ page 32

The Pharmacologist is published and distributed by the American Society for Pharmacology and Experimental Therapeutics.

Editor
Christine K. Carrico, Ph.D.

EDITORIAL ADVISORY BOARD
Donald E. McMillan, Ph.D.
Kim A. Neve, Ph.D.
Patricia K. Sonsalla, Ph.D.

COUNCIL
President
David B. Bylund, Ph.D.
President-Elect
Stephen G. Holtzman, Ph.D.
Past President
Paul F. Hollenberg, Ph.D.
Secretary/Treasurer
Cinda J. Helke, Ph.D.
Secretary/Treasurer-Elect
James R. Halpert, Ph.D.
Past Secretary/Treasurer
James E. Barrett, Ph.D.
Councilors
Donald E. McMillan, Ph.D.
Kim A. Neve, Ph.D.
Patricia K. Sonsalla, Ph.D.
Chair, Board of Publications Trustees
Brian M. Cox, Ph.D.
Chair, Program Committee
Lynn Wecker, Ph.D.
Executive Officer
Christine K. Carrico, Ph.D.

The Pharmacologist, (ISSN 0031-7004), 9650 Rockville Pike, Bethesda, MD 20814-3995, is published quarterly by the American Society for Pharmacology and Experimental Therapeutics. The subscription rate for domestic nonmembers and institutions is $40.00 per year and $60.00 per year for foreign and Canadian nonmembers and institutions. Individual issues may be purchased for $15.00 plus shipping and handling. Copyright ©2004 by the American Society for Pharmacology and Experimental Therapeutics, Inc. All rights reserved. Periodicals postage paid at Bethesda, MD. The GST number for Canadian subscribers is BN: 13489 2330 RT.

ASPET assumes no responsibility for the statements and opinions advanced by contributors to The Pharmacologist.

Deadlines for submission of material for publication: Issue 1, March 1; Issue 2, June 1; Issue 3, September 1; and Issue 4, December 1.

Postmaster: Send address changes to: The Pharmacologist, ASPET, 9650 Rockville Pike, Bethesda, MD 20814-3995.
ASPET AWARD WINNERS FOR 2004

David P. Siderovski, Ph.D.
J.J. Abel Award

Dr. David P. Siderovski, Assistant Professor in the Department of Pharmacology at the University of North Carolina at Chapel Hill, is the recipient of the 2004 John J. Abel Award, sponsored by Eli Lilly. Dr. Siderovski receives the John J. Abel Award as an outstanding young investigator for his contributions that have helped shape the field of pharmacology.

Dr. Siderovski received his B.Sc. from Queens University in Ontario, Canada and his Ph.D. from the University of Toronto. While working as Head of the Quantitative Biology Laboratory at the Amgen Institute in Toronto, Dr. Siderovski was one of the first scientists to identify the regulators of the G-protein signaling (RGS) protein superfamily. He has continued this pioneering research, applying bioinformatics and structural biological techniques to discover novel functional domain structures within RGS family members, and has achieved national and international recognition for his critical re-appraisal of previously established dogmas in the field of G protein-coupled receptor signaling. Dr. Siderovski’s current work focuses on elucidating the specific roles of RGS proteins as “kinetic scaffolds” in the coordination of multiple signal transduction pathways, as well as in the spatial and temporal regulation of neurotransmitter signaling in the brain.

Philip Needleman, Ph.D.
Pharmacia ASPET Award for Experimental Therapeutics

Dr. Phillip Needleman, Adjunct Professor of Molecular Biology and Pharmacology at Washington University in St. Louis and Partner in Prospect Venture Partners, is the recipient of the 2004 Pharmacia-ASPET Award for Experimental Therapeutics. Dr. Needleman received his B.S. and M.S. from the Philadelphia College of Pharmacy and his Ph.D. in Pharmacology from the University of Maryland Medical School. After completing a postdoctoral fellowship at Washington University in St. Louis, he joined the faculty and was Chairman of the Department of Pharmacology from 1976-1989. Prior to his current position, he was Chief Scientific Officer and Senior Executive Vice President and Chairman of Research & Development at Pharmacia Corporation and held other positions at G.D. Searle and Monsanto.

Dr. Needleman’s scientific contributions have been in all phases of drug discovery and development. He made the seminal observation leading to the discovery and characterization of COX-2 and the formulation of the hypothesis that specific inhibition of COX-2 would provide the therapeutic benefits of NSAIDS without their serious associated toxicity. He led the pharmaceutical team that developed chemical entities exhibiting great inhibitory specificity for COX-2 and minimal such activity against COX-1. His research group showed that these new therapeutic classes of anti-inflammatory agents exhibit pain control and the exciting new possibility of preventing or delaying cancer development. His work has helped in the development of the blockbuster drug Celebrex, and he has been instrumental in developing the careers of many successful scientists.

Lee E. Limbird, Ph.D.
Goodman & Gilman Award in Drug Receptor Pharmacology

Lee E. Limbird, Ph.D., Professor of Pharmacology and Associate Vice Chancellor for Research at Vanderbilt University Medical Center, is the winner of the 2004 Goodman and Gilman Award sponsored by ASPET and GlaxoSmithKline. Dr. Limbird receives the Goodman and Gilman Award for her pioneering work and contributions to our understanding of α2-adrenergic receptors.

Dr. Limbird received her B.A. in Chemistry from the College of Wooster in Wooster, Ohio and Ph.D. in biochemistry from the University of North Carolina at Chapel Hill. She began her work on adrenergic receptors, focusing on β-adrenergic receptors and their regulation of adenyl cyclase through G proteins, during her postdoctoral work at Duke University. After two years as Assistant Professor in the
Department of Medicine at Duke University, Dr. Limbird moved to Vanderbilt University where she began her study on $\alpha_2$-adrenergic receptors, work which she has continued to the present and which has resulted in many seminal contributions to the field. These include discovery of the basis for $\alpha_2$-adrenergic receptor subtype activation of G proteins, the coupling of these receptors to multiple chemical and electrical signaling pathways, and the basis for how the same receptor can couple to different signaling pathways in neuronal versus non-neuronal cells. Dr. Limbird has used mice genetically engineered in her laboratory to provide definitive evidence for the therapeutic selectivity that can be achieved by partial agonists at $\alpha_2$-adrenergic receptors, a finding with major clinical implications. These same mice have revealed the role of this receptor subtype in sedation, anesthetic sparing, suppression of pain perception, synergism with opioids in producing analgesia, in the regulation of blood pressure and enhancement of working memory.

Dr. Limbird’s research has provided us with great insights not only into the role of the $\alpha_2A$ receptor subtype in physiological and pharmacological processes but also, by extension, insights into the role of the other $\alpha_2$ subtypes and the role of the other adrenergic receptors. Dr. Limbird’s work in this area has resulted in the publication of 135 papers and book chapters.

In addition to her pioneering research, Dr. Limbird has played a major role in the teaching of pharmacology. She has been an editor of several outstanding textbooks, including editions of Goodman and Gilman’s *The Pharmacological Basis of Therapeutics*, the gold standard of textbooks in pharmacology. Dr. Limbird also served as Chair of the Department of Pharmacology at Vanderbilt for seven years.

**Thomas L. Poulos, Ph.D.**

*B. B. Brodie Award in Drug Metabolism*

Dr. Thomas L. Poulos is the winner of the 2004 Bernard B. Brodie Award in Drug Metabolism. The Award is given every other year and honors the fundamental contributions of Bernard B. Brodie in the field of drug metabolism. Dr. Poulos received his B.A. from the University of California at Santa Barbara and Ph.D. from the University of California at San Diego.

Dr. Poulos has been a pioneer in one of the major developments in drug metabolism research, notably characterizing cytochrome P450 enzymes. Knowledge of the three-dimensional structure of P450 enzymes, the major enzymes of drug metabolism, serves as the basis for all of the rational approaches to the design of selective drug metabolism inhibitors. Dr. Poulos’ breakthrough research propelled research in drug metabolism in new, exciting and unprecedented directions in both academia and the pharmaceutical industry. Because of its relevance to clinical drug-drug interactions, it soon became an important cornerstone for new drug design and development.

**Dr. Poulos will give the B. B. Brodie Lecture, titled “Structural and Functional Diversity in Heme Monoxygenases,” on Monday, April 19 at 1:45 p.m. in room 144C in the Washington Convention Center.**

**Joseph V. Brady, Ph.D.**

*P.B. Dews Award in Behavioral Pharmacology*

Dr. Joseph V. Brady, Director of the Behavioral Biology Research Center at Johns Hopkins Medical Center, is the winner of the 2004 P.B. Dews Lifetime Achievement Award in Behavioral Pharmacology. The award is given every other year and honors the fundamental contributions of P.B. Dews to behavioral pharmacology. Dr. Brady received his B.S. from Fordham University and Ph.D. from the University of Chicago.

After completion of his Ph.D. in 1951, Dr. Brady went to the Walter Reed Institute of Research where he joined one of the first interdisciplinary neuropsychiatric research teams and began two productive decades in the laboratory. He collaborated on some landmark studies in what was then identified as “physiological psychology” but is now known as “behavioral neuroscience.” A series of papers in the 1950s not only showed the usefulness of animal models of “emotional behavior” for testing the effects of psychoactive drugs, but led to the enthusiastic embrace of behavioral pharmacology by the pharmaceutical industry. Dr. Brady received one of the earliest grants from the National Institute for Mental Health to establish the first Behavioral Pharmacology
Center at the University of Maryland in College Park. The advent of the Sputnik era launched Dr. Brady's career into another
direction. He was responsible for training the monkeys who were the first U.S. organisms to brave space flight in the nose cone of one
of Werner von Braun's ballistic missiles. He was involved in animal pretest flights including the first orbital flight with John Glenn's
predecessor, the chimpanzee named Ham. Dr. Brady would later establish a human programmed environment research laboratory at
the Johns Hopkins University School of Medicine. He founded the Division of Behavioral Biology in the Department of Psychiatry
and Behavioral Sciences at Johns Hopkins and for more than three decades has continued to direct research and educational activities
at the medical school in the areas of behavior analysis and behavioral physiology, pharmacology, and medicine. Dr. Brady was a
founder of the American College of Neuropsychopharmacology.

Dr. Brady will give the P.B. Dews Award Lecture, entitled “The Origin and Development of Behavioral
Pharmacology,” on Monday, April 19 at 1:45 p.m. in room 143C in the Washington Convention Center.

### Graduate Student Travel Award Winners

<table>
<thead>
<tr>
<th>Name</th>
<th>University/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salim Al-Rejaie</td>
<td>East Carolina Univ</td>
</tr>
<tr>
<td>Anthony J. Baucum II</td>
<td>Univ of Utah</td>
</tr>
<tr>
<td>Tabetha M. Bonacci</td>
<td>Univ of Rochester</td>
</tr>
<tr>
<td>Joseph M. Breier</td>
<td>Boston Univ Sch of Med</td>
</tr>
<tr>
<td>Lawrence P. Carter</td>
<td>Univ of Texas HSC at San Antonio</td>
</tr>
<tr>
<td>Zhongjian Chen</td>
<td>Emory Univ</td>
</tr>
<tr>
<td>Ananya De</td>
<td>Univ of Minnesota</td>
</tr>
<tr>
<td>Marcus Delatte</td>
<td>LSU Health Sciences Center</td>
</tr>
<tr>
<td>Efrain E. Garcia</td>
<td>Vanderbilt Univ School of Med</td>
</tr>
<tr>
<td>Akanksha Gupta</td>
<td>North Dakota State Univ</td>
</tr>
<tr>
<td>Sumaya Nizar Hamadmad</td>
<td>Univ of Iowa Col of Med</td>
</tr>
<tr>
<td>Richard G. Hunter</td>
<td>Yerkes Natl Primate Ctr, Emory Univ</td>
</tr>
<tr>
<td>Karen M Kassel</td>
<td>Univ of Nebraska Med Center</td>
</tr>
<tr>
<td>Irene K. Klein</td>
<td>Univ of Illinois-Chicago</td>
</tr>
<tr>
<td>Xiaoying Kong</td>
<td>Northeastern Ohio Univ Col of Med</td>
</tr>
<tr>
<td>Elizabeth M. Lapoczka</td>
<td>Univ of Michigan</td>
</tr>
<tr>
<td>Tiangang Li</td>
<td>Northeastern Ohio Univ Col of Med</td>
</tr>
<tr>
<td>Yun Liu</td>
<td>Univ of Oklahoma HSC</td>
</tr>
<tr>
<td>Reijun Liu</td>
<td>Drexel Univ</td>
</tr>
<tr>
<td>Amie K. Lund</td>
<td>Univ of New Mexico</td>
</tr>
<tr>
<td>Megan M. McNulty</td>
<td>Univ of Chicago</td>
</tr>
<tr>
<td>Tanvi D. Modi</td>
<td>Univ of Louisville</td>
</tr>
<tr>
<td>Lauren J. Murphree</td>
<td>Univ of Virginia</td>
</tr>
<tr>
<td>Noha Nagah Soliman Nassar</td>
<td>Brody Sch Of Med, East Carolina Univ</td>
</tr>
<tr>
<td>Demian F. Obregon</td>
<td>Tulane Univ HSC</td>
</tr>
<tr>
<td>Alex A. Pérez-Rivera</td>
<td>Michigan State Univ</td>
</tr>
<tr>
<td>Preeti Puntambekar</td>
<td>Southern Illinois Univ</td>
</tr>
<tr>
<td>Ali Razmara</td>
<td>Univ of California, Irvine</td>
</tr>
<tr>
<td>James M Sanders</td>
<td>Univ of Texas Med Branch, Galveston</td>
</tr>
<tr>
<td>Janelle Y. Sautler</td>
<td>UNC-Chapel Hill</td>
</tr>
<tr>
<td>Sharmilee P. Sawant</td>
<td>Univ of Louisiana at Monroe</td>
</tr>
<tr>
<td>Jianzhong Shen</td>
<td>Univ of Missouri Sch of Med</td>
</tr>
<tr>
<td>Thomas C. Stover</td>
<td>Penn State Col of Med</td>
</tr>
<tr>
<td>Jeffery N. Talbot</td>
<td>Univ of Nebraska Med Center</td>
</tr>
<tr>
<td>Huda Tawfik</td>
<td>Brody Sch of Med, East Carolina Univ</td>
</tr>
<tr>
<td>Banu C. Tel</td>
<td>King's Col London</td>
</tr>
<tr>
<td>Meghna Trivedi</td>
<td>Univ of Houston</td>
</tr>
<tr>
<td>Kedar S. Vaidya</td>
<td>Univ of Louisiana at Monroe</td>
</tr>
<tr>
<td>Fei Wang</td>
<td>Univ of Florida Col of Med</td>
</tr>
<tr>
<td>Sunmee Wee</td>
<td>Univ of Mississippi Med Ctr</td>
</tr>
<tr>
<td>Yan Weng</td>
<td>SUNY at Albany, Sch of Public Health</td>
</tr>
<tr>
<td>Alexander C. Whitley</td>
<td>Medical Univ of South Carolina</td>
</tr>
<tr>
<td>Yang Zhang</td>
<td>Medical Col of Wisconsin</td>
</tr>
</tbody>
</table>

### Young Scientist Travel Award Winners

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey M. Brown</td>
<td>Boston Univ Med Center</td>
</tr>
<tr>
<td>Scott A. Chen</td>
<td>Scripps Research Institute</td>
</tr>
<tr>
<td>Songhai Chen</td>
<td>Vanderbilt Univ Med Center</td>
</tr>
<tr>
<td>Andreas Gille</td>
<td>Univ of Kansas</td>
</tr>
<tr>
<td>Rayna J. Gonzales</td>
<td>Univ of California, Irvine</td>
</tr>
<tr>
<td>Brett M. Mitchell</td>
<td>Universities Space Research Assoc</td>
</tr>
<tr>
<td>Carrie A. Northcott</td>
<td>Michigan State Univ</td>
</tr>
<tr>
<td>Hemal H. Patel</td>
<td>Univ of California, San Diego</td>
</tr>
<tr>
<td>Jason N. Peart</td>
<td>Medical Col of Wisconsin</td>
</tr>
<tr>
<td>Doodipala S. Reddy</td>
<td>North Carolina State Univ</td>
</tr>
<tr>
<td>Chantal A. Rivera</td>
<td>Baylor Univ</td>
</tr>
<tr>
<td>Shiladiya Sengupta</td>
<td>MIT</td>
</tr>
<tr>
<td>Glenn W. Stevenson</td>
<td>McLean Hospital/Harvard</td>
</tr>
<tr>
<td>Raghavendra Vasudeva</td>
<td>Dartmouth-Hitchcock Med Ctr</td>
</tr>
<tr>
<td>Francis S. Willard</td>
<td>Univ of North Carolina at Chapel Hill</td>
</tr>
<tr>
<td>Hui Xu</td>
<td>Michigan State Univ</td>
</tr>
</tbody>
</table>

### SURF Travel Award Winners

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward K. Brown, Jr.</td>
<td>Temple Univ School of Pharmacy</td>
</tr>
<tr>
<td>Yerai Olveras-Sanchez</td>
<td>Univ of Puerto Rico</td>
</tr>
</tbody>
</table>

ASPET thanks the following companies for their support of the Graduate Student Travel Award Program: Abbott Laboratories, Berlex Laboratories, Merck Research Laboratories, Millennium Pharmaceuticals, and Wyeth Research.
CALL FOR AWARD NOMINATIONS FOR 2005

THE TORALD SOLLMANN AWARD
IN PHARMACOLOGY INVESTIGATION & EDUCATION

The Torald Sollmann Award in Pharmacology was established to commemorate the pioneer work of Dr. Torald Sollmann in the fields of pharmacological investigation and education. Sponsored by Wyeth Research, the Torald Sollmann Award is presented biennially in odd years for significant contributions over many years to the advancement and extension of knowledge in the field of pharmacology. The award consists of an honorarium of $3,500, a medal, and travel expenses for the winner and spouse to the annual meeting. The formal presentation of this biennial award and medal will be made at the annual meeting of ASPET. The recipient will be invited by the President of the Society to deliver a Sollmann Oration to the membership that may be published in an appropriate ASPET journal.

There are no restrictions on nominees for this award. However, a nomination must be made by a member of the American Society for Pharmacology and Experimental Therapeutics (ASPET), and no member may nominate more than one candidate in a year. The award shall be made on the basis of originality and uniqueness of accomplishments throughout a long career distinguished by sustained, significant contributions to education, research, and service in pharmacology. Selection of the recipient will be made by the Torald Sollmann Award Committee, consisting of five present and former members of the ASPET Council, with the Senior Councilor serving as chair.

Nominations shall be accompanied by six (6) copies of each of the following:

1. **No more than** five letters from nominators describing the contributions to pharmacology of the candidate that make him/her eligible for this Award, listing major contributions.
2. Brief biographical sketch of the candidate.
3. Candidate’s *curriculum vitae* and bibliography.

Nominations for the 2005 Award must be received no later than **September 15, 2004** by the Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Maryland 20814-3995.

<table>
<thead>
<tr>
<th>Year</th>
<th>Nominee</th>
</tr>
</thead>
<tbody>
<tr>
<td>1961</td>
<td>Otto Krayer</td>
</tr>
<tr>
<td>1963</td>
<td>Bernard B. Brodie</td>
</tr>
<tr>
<td>1966</td>
<td>Arnold D. Welch</td>
</tr>
<tr>
<td>1969</td>
<td>Earl W. Sutherland, Jr.</td>
</tr>
<tr>
<td>1973</td>
<td>Julius Axelrod</td>
</tr>
<tr>
<td>1975</td>
<td>Sidney Udenfriend</td>
</tr>
<tr>
<td>1981</td>
<td>Avram Goldstein</td>
</tr>
<tr>
<td>1984</td>
<td>K. K. Chen</td>
</tr>
<tr>
<td>1986</td>
<td>Walter K. Riker</td>
</tr>
<tr>
<td>1988</td>
<td>James A. Bain</td>
</tr>
<tr>
<td>1990</td>
<td>George B. Koelle</td>
</tr>
<tr>
<td>1992</td>
<td>E. Leong Way</td>
</tr>
<tr>
<td>1995</td>
<td>Theodore M. Brody</td>
</tr>
<tr>
<td>1997</td>
<td>Alfred G. Gilman</td>
</tr>
<tr>
<td>1999</td>
<td>William W. Fleming</td>
</tr>
<tr>
<td>2001</td>
<td>Benedict R. Lucchesi</td>
</tr>
<tr>
<td>2003</td>
<td>Palmer W. Taylor</td>
</tr>
</tbody>
</table>

**JOHN J. ABEL AWARD**

The John J. Abel Award in Pharmacology, supported by Eli Lilly and Company, was established to stimulate fundamental research in pharmacology and experimental therapeutics by young investigators. The annual Award consists of $2,500, a bronze medal, and travel expenses for the winner and spouse to the award ceremony at the annual meeting of ASPET.

Nominees for this award shall not have passed their **thirty-ninth birthday on April 30** of the year of the Award. The candidate need not be a member of the Society; however, a nomination must be made by an ASPET member, and no member may nominate more than one candidate a year. The Award shall be made for original, outstanding research in the field of pharmacology and/or experimental therapeutics. Independence of thought, originality of approach, clarity and excellence of data presentation are important criteria. Candidates shall not be judged in comparison with the work of more mature and experienced investigators. Quality rather than the number of contributions shall be emphasized. It shall be the responsibility of the sponsor to make clear the contribution of the candidate to any jointly authored reprints and manuscripts and the originality and independence of the candidate’s research. Selection will be made by the J.J. Abel Award Committee, appointed by the President of ASPET.
CALL FOR AWARD NOMINATIONS FOR 2005

Nominations shall be accompanied by six (6) copies of each of the following:
1. Summary that describes the importance of the candidate’s work.
2. Each of six published articles or manuscripts accepted for publication that are a representation of the candidate’s work.
3. Brief biographical sketch of the candidate.
4. Candidate’s curriculum vitae and bibliography.

Nominations for this Award must be received no later than September 15, 2004 by the Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Maryland 20814-3995.

Winners of the John J. Abel Award


THE PHARMACIA-ASPET AWARD IN EXPERIMENTAL THERAPEUTICS

The Pharmacia-ASPET Award in Experimental Therapeutics is given annually to recognize and stimulate outstanding research in pharmacology and experimental therapeutics—basic laboratory or clinical research that has had, or potentially will have, a major impact on the pharmacological treatment of disease. The award is supported in perpetuity by a gift from Pharmacia. The winner will receive a $2,500 honorarium, a bronze medal, and travel expenses for the winner and spouse to the award ceremony at the ASPET annual meeting.

There are no restrictions on nominees for this award. The Award shall be made on the basis of published reprints, manuscripts ready for publication, and a two-page summary. Selection will be made by the Pharmacia-ASPET Award Committee, appointed by the President of ASPET.

Nominations shall be accompanied by six (6) copies of each of the following:
1. Two (2)-page summary that details the importance of the candidate’s work.
2. Each of six articles published or ready for publication by the candidate that have direct bearing on the Award.
3. Brief biographical sketch of the candidate.
4. Candidate’s curriculum vitae and bibliography.

Nominations for this Award must be received no later than September 15, 2004 by the Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Maryland 20814-3995.
CALL FOR AWARD NOMINATIONS FOR 2005

Winners of the ASPET Award for Experimental Therapeutics

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Year</th>
<th>Name</th>
<th>Year</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1971</td>
<td>Elliot S. Vesell</td>
<td>1984</td>
<td>Sir James Black</td>
<td>1997</td>
<td>Michael M. Gottesman</td>
</tr>
<tr>
<td>1972</td>
<td>Francois M. Abboud</td>
<td>1985</td>
<td>Louis Lemberger</td>
<td>1998</td>
<td>Phil Skolnick</td>
</tr>
<tr>
<td>1979</td>
<td>Sydney Spector</td>
<td>1992</td>
<td>James W. Fisher</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1980</td>
<td>Sanford M. Rosenthal</td>
<td>1993</td>
<td>V. Craig Jordan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1981</td>
<td>David G. Shand</td>
<td>1994</td>
<td>Susan B. Horwitz</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

EPILEPSY RESEARCH AWARD FOR OUTSTANDING CONTRIBUTIONS TO THE PHARMACOLOGY OF ANTIEPILEPTIC DRUGS

The Epilepsy Award is sponsored by The International League Against Epilepsy (ILAE) and donated by Pfizer for the purpose of recognizing and stimulating outstanding research leading to better clinical control of epileptic seizures. This research may include the basic screening and testing of new therapeutic agents, studies on mechanisms of action, metabolic disposition, pharmacokinetics, and clinical pharmacology studies. This Award, presented biennially in odd years, consists of an honorarium of $2,000, a Certification of Citation, and travel expenses to the awards ceremony at the ASPET annual meeting.

Nominees for the 2005 award must be actively engaged in the research for which the Award is made, and primary emphasis will be placed upon work accomplished in the five-year period prior to the Award. Nominations for the Award may be submitted by members of any recognized scientific association, domestic or foreign. Selection of an awardee will be made biennially by the Epilepsy Award Committee appointed by the President of ASPET, with representation of ILAE.

Nominations shall be accompanied by six (6) copies of each of the following:

1. Summary describing the nominee’s major achievements.
2. Nominee’s six most significant papers, including manuscripts accepted for publication.
3. Brief biographical sketch of the candidate.
4. Nominee’s curriculum vitae and bibliography.

Nominations for this Award must be received no later than September 15, 2004 by the Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Maryland 20814-3995.

Winners of the Epilepsy Award

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Year</th>
<th>Name</th>
<th>Year</th>
<th>Name</th>
</tr>
</thead>
</table>
Sir James W. Black, of the James Black Foundation in London, will give the John V. Croker Lecture at Experimental Biology '04. Professor Black will speak on Monday, April 19 at 8:15 am in Room 144AB in the new Washington Convention Center. His talk is titled “Dose-Response Expectations in Therapeutics.”

Professor Black, along with Dr. Gertrude Elion and Dr. George Hitchings, won the Nobel Prize in Physiology or Medicine in 1988 for his realization of the potential of receptor-blocking drugs in therapeutics. He developed the first clinically useful beta adrenergic receptor blocking drug, propranolol. Subsequently, he identified the separate class of histamine-2 receptors which led to one of the first blockbuster drugs, cimetidine.

EB ’04 Obesity Programming – It’s worth the weight!
In addition to the ASPET-Ray Fuller Symposium, “Pharmacotherapy of Obesity: Targets and Tools for the 21st Century,” being held on Friday, April 16 (see announcement on page 16), there are several other sessions offered by ASPET and other EB societies related to the topic of Obesity during the main course of the meeting.

Sunday April 18

Symposium-ASPET, 9:30 am – 12:00 noon, CC 143C

Chronic calorie restriction prevents obesity-associated increases in liver triglyceride but not age-related increases in muscle triglyceride, H.K. Ortmeyer, C. Collins, A. Tison, A.P. Goldberg and B.C. Hansen
Minisymposium talk-ASNS, 11:45 am – 12:00 noon, CC 150B

Obesity, Nutritional Aspects – Carbohydrates
Poster session-ASNS, 12:45 – 2:45 pm, CC Exhibit Hall B

Obesity and leptin-receptor gene polymorphisms among postmenopausal women, C.L. Carpenter, S. Ingles, V. Jaque, E. Schroeder, H-L. Wong and L. Bernstein
Minisymposium – ASNS, 3:00 – 3:15 pm, CC 154 (part of a minisymposium)

Emerging Concepts and Compounds in Obesity Therapeutics (Chairs: T.J. Opgenorth and L.A. Tartaglia)
Symposium-ASPET, 3:00 – 5:30 pm, CC 143C

Monday April 19

Therapeutic Opportunities for H3 Receptor Ligands (Chair: A. A. Hancock)
Symposium-ASPET, 9:30 am – 12:00 noon, CC 143C

Regulation of Food Intake and Obesity
Poster session - ASPET, 12:30 – 2:45 pm, CC Exhibit Hall AB
Tuesday April 20

Gender and the Pharmacology of Eating Disorders: Linking Molecules and Signals to Behavior (Chair: J.M. Lakoski)
Symposium-ASPET, 9:30 am - 12:00 noon, CC 143C

Obesity, Nutritional Aspects (Chairs: B. Tohill and M. McCrory)
Minisymposium-ASNS, 8:00 – 10:00 am, CC 150A

Obesity, Nutritional Aspects – Dietary Components
Poster Session-ASNS, 12:45 – 2:45 pm, CC Exhibit Hall AB

Obesity, Nutritional Aspects - Behavioral
Poster Session-ASNS, 12:45 – 2:45 pm, CC Exhibit Hall AB

Obesity, Nutritional Aspects – Adipocytes, Differentiation and Signaling
Poster Session-ASNS, 12:45 – 2:45 pm, CC Exhibit Hall AB

Central Autonomic Regulation III: Obesity and Metabolic Regulation
Poster Session-APS, 12:45 – 3:00 pm, CC Exhibit Hall AB

Food Intake Regulation II (Chairs: B. Rolls and J. Fisher)
Minisymposium-ASNS, 3:00 – 5:00 pm, CC 152B

Wednesday April 21

Obesity and Satiety
Poster Session-APS, 12:45 – 3:00 pm, CC Exhibit Hall AB

ASPET Divisional Programming

★Division for Behavioral Pharmacology Workshop: Quantitative methods in behavioral pharmacology
Monday, April 19, 3:00 – 5:30 pm, CC 143C
Moderator: J.L. Katz
Opioid agonist interactions in rhesus monkeys: A case study of dose-addition analysis and the evaluation of drug combinations.
Self-administration of drug mixtures. W.L. Woolverton, Univ. of Mississippi Med. Ctr.

★Division for Cardiovascular Pharmacology Graduate Student and Postdoctoral Scientist Best Paper Competition
Monday, April 19, 3:00 – 5:30 pm, CC 143AB
Chairs: S.P. Jones and R. H. Kennedy

★Division for Clinical Pharmacology Symposium: Mechanisms of gender effects on human drug response
Tuesday, April 20, 3:00 – 5:30 pm, CC 142
Chair: D.A. Flockhart
Mechanisms of gender effects on pharmacodynamics: Ion channel activity. Steven N. Ebert, Georgetown Univ. Med. Ctr.
Mechanisms of gender effects on pharmacokinetics. J. Christopher Gorski, Indiana Univ. Sch. of Med.
Mechanisms of gender effects on disease: Gender differences in intermediate phenotypes' for hypertension. Daniel T. O'Connor, UCSD
**Division for Drug Discovery, Development and Regulatory Affairs** Symposium: Drug discovery and development: From idea to approval  
Monday, April 19, 3:00 – 5:30 pm, CC 142  
Chair: B. Yerxa  
- Drug discovery: Finding new targets and active compounds. H. Jefferson Leighton, BioDesign, Boston, MA  
- Drug development: Establishing clinical human safety and efficacy. Karla Jacobus, PPD Develop., Morrisville, NC  
- Drug approval: The FDA and the regulatory process. Pauliana Hall, PCH Integrated Regulatory Services, Laguna Niguel, CA

**Division for Drug Metabolism** Platform Session: Biotransformation and drug transport  
Wednesday, April 21, 9:30 am – 12:00 noon, CC 158  
Chairs: M. R. Franklin and T. S. Tracy  
- Includes presentations by Jim Gillette Best Manuscript Award winners

**Division for Molecular Pharmacology** Postdoctoral Award Finalists  
Monday April 19, 3:00 - 5:30 pm, CC-144AB  
Chair: P. W. Taylor  
- A new approach to structure-guided drug design: Fluctuations in the drug target and freeze frame inhibition. Palmer W. Taylor, UCSD

**Division for Neuropharmacology** Symposium: Cell biology of the catecholamine neuron: A symposium in honor of Julius Axelrod  
celebrating a decade of molecular exploration of mammalian phenotypes of catecholamine biosynthetic enzyme, transporter and metabolizing enzyme deficiency, and their clinical relevance to neuronal excitability, food- and drug-related behaviors, and neuronal development and degeneration.  
Tuesday, April 20, 3:00 – 5:30 pm, CC 144AB  
Chair: L. Eiden  
- Introduction. Solomon Snyder, Johns Hopkins.  
- Disruption of striatal dopamine signaling causes amphetamine-induced hypophagia. Richard Palmiter, Univ. of Washington.  
- The vesicular monoamine transporters and other regulated traits of monoamine-secreting cells. Lee E. Eiden, NIMH-IRP, NIH  
- COMT: From gene to brain and behavior. Daniel Weinberger, NIMH-IRP, NIH

**Division for Pharmacology Education** Workshop: Team learning: Small-group activities in the large-group lecture hall  
Monday April 19, 9:30 am – 11:30 am  
Moderators: C. L. Seidel and K. K. McMahon  
- Lectures remain the main instructional modality because they are efficient and summarize large bodies of material. However, learners are passive recipients of information. To increase active learning, small-groups have been adopted. This allows problem solving and application of knowledge in real-life situations but demands faculty and facilities and can result in uneven inter-group instruction. Team Learning (TL) combines the strengths of lectures and small-groups. TL consists of three phases. In Phase 1 learners acquire required content through self-study, lectures or both. In Phase 2 learners demonstrate their readiness to apply information through tests taken individually and in small-groups, followed immediately by faculty feedback. In Phase 3 students solve problems in small-groups in the lecture hall. Keys to this phase are that groups work on the same problem, select their solution from a list, and simultaneously declare their selection. Problems are designed to generate inter-group controversy which faculty exploit as groups orally defend their selections. The rich discussion enables faculty to correct student thinking and model critical thinking.

This two-hour workshop will expose participants to the principles of Team Learning through their participation in a mock course using Team Learning. At key intervals participants will reflect on specific Team Learning principles to learn more about the process and to appreciate how Team Learning may be applied to their specific circumstance. By the end of the workshop, participants will be able to describe the three phases of Team Learning, define differences between Readiness Assurance Tests and Group Activity questions, and describe the elements of a good Group Activity question.
Division for Systems and Integrative Pharmacology Symposium: Calcium mobilization to calcium sensitization: Identifying new pharmacologic targets in smooth muscle
Tuesday, April 20, 3:00 – 5:30 pm, CC 143C
Chairs: George Christ and Chris Wingard
- Regulation of Ca\(^{2+}\)-mobilization in detrusor muscle. Gerry Herra, Univ. of Vermont Col. of Med.
- K\(^+\) channels, gap junctions and smooth muscle. George J. Christ, Albert Einstein Col. of Med.
- Actin cytoskeletal remodeling in smooth muscle. William T. Gerthoffer, Univ. of Nevada Sch. of Med.
- ROS and Ca\(^{2+}\)-sensitivity in smooth muscle. Keith A. Jones, Mayo Clinic
- EETs and ionic conductance systems in cerebral vascular muscle. David R. Harder, Med. Col. of Wisconsin

Division for Toxicology Symposium: Hepatotoxicity: Signaling mechanisms in cell death and survival
Tuesday, April 20, 3:00 – 5:30 pm, CC 144C
Chair: Harihara M. Mehendale
- Mechanisms of acetaminophen hepatotoxicity: Oxidant stress and regeneration. Hartmut Jaeschke, Univ. of Arizona
- Inflammation: A susceptibility factor in drug-induced liver injury. Robert A. Roth, Michigan State Univ.
- Survival mechanisms in fatty hepatocytes. Anna Mae Diehl, Johns Hopkins, Univ.
- Mechanisms of progression and regression in liver injury. Harihara M. Mehendale, Univ. of Louisiana at Monroe

Second RGS Protein Colloquium
Saturday, April 17, 2004
Renaissance Hotel, Washington, DC
9:00 am – 6:00 pm
Chairs: Vadim Arshavsky and David Siderovski

RGS proteins: Past, present, future
David Siderovski, UNC - Chapel Hill
Mechanisms of feedback inhibition by RGS protein induction and turnover
Henrik Dohlman, UNC - Chapel Hill
RGS protein control of centrosome movement during mitosis in C. elegans embryos
Michael Koelle, Yale U.
Role of the RGS domain in G protein-coupled receptor kinase function
Jeffrey Benovic, Thomas Jefferson U.
RGS insensitive G proteins as probes of physiological RGS function
Richard Neubig, U. Mich
Regulation of vascular smooth muscle relaxation and blood pressure by RGS2
Michael Mendelsohn, Tufts U.
Investigation of RGS proteins toward modulation of neurobiological disorders
Kathleen Young, Wyeth Research
Functional analysis of RGS proteins in intact cells: Lessons from photoreceptors
Marie Burns, UC-Davis
Building RGS protein specificity through its domain composition
Vadim Arshavsky, Harvard Medical School and Massachusetts Eye and Ear Infirmary, Boston

Registration Deadline: March 31, 2004. This is a satellite meeting to Experimental Biology 2004. Separate registration is required.

Registration information is available online at www.aspet.org/public/meetings. Select Second RGS Colloquium. Or contact Margie Arkin, 301-634-7989, markin@aspet.org

Presented by: The Division for Molecular Pharmacology of the American Society for Pharmacology and Experimental Therapeutics.
Instructions for Oral Presentations

New This Year – You do not need to bring a computer

- Recommended method for having your presentation projected.

All EB session rooms will be equipped with a data projector and computer. Bring your presentation on a Windows readable CD-ROM, 250 MB Zip Disk, or 3 ½” floppy disk.

When building your presentation, make sure you include, in the same folder as your presentation, any external files utilized, i.e. movie files. Copy the entire folder to the disk. Review these specifications when preparing your presentation. The computers will support PC and Mac presentations. The operating system will be Windows XP Professional, and software will include:

- Powerpoint 2002
- CorelDRAW 10
- Adobe Acrobat PDF file based
- QuickTime

We recommend that you bring a backup presentation format to cover the possibility of luggage loss, theft, and/or incompatibility.

Go to the Speaker Practice Room at least 24 hours in advance of your presentation to verify that the presentation will function on the equipment provided.

- Bringing your own laptop.

You do not need to bring your own laptop. However, there will be connections available for presenters to use their own laptops. Speakers using their own laptops MUST HAVE a VGA HD15pin female output. Some laptops have special video output cables to get to the HD15pin required for connecting to external monitors and data projectors. If this cable is not with the laptop being used there is no way to connect to a Data Projector. The laptop output resolution should be no more then XGA (1024x768). The native resolution on the data projectors is 1024x768, so higher resolutions will force the data projector into a compression mode, possibly losing some information or not projecting.

- Projection of 2x2 slides is not supported.

Projectors for 2x2 slides will not be provided unless requested in advance of the meeting. The demand for this format has fallen in recent years, and EB is encouraging the use of electronic formats.

Speaker Practice Rooms will be located in the Washington, DC Convention Center. The rooms will be open Saturday through Wednesday from 9:00 am – 5:00 pm. All speakers should check their presentation 24 hours in advance and arrive in the session room ½ hour before the session starts.
Public Affairs Workshops and Symposia
Open to all EB registrants

Saturday, April 17

Human Research Protections 1a: How to Navigate Human Research Protection Regulations
http://www.asip.org/mtgs/EB04/hrtpp.htm
9:00 am - 11:00 am
Convention Center, Room 101

This workshop will provide an introduction to principles of bioethics and current U.S. federal regulations for protecting human subjects involved in research. The workshop will describe a comprehensive program of protections that an institution can provide to effectively protect human subjects and simultaneously conduct good scientific research. Emphasis will be on the roles of Institutional Review Boards (IRBs) and investigators in protecting research subjects and will include a comparison of the “Common Rule” with HIPAA concerning the use of human biological materials. There is no charge for this session, but seating is limited, so you must register to attend. Contact: Tara Zeitner at 301-634-7950.

IACUC 101 for Scientists: Dealing With Problem Areas
http://www.the-aps.org/pa/IACUC/eb04.htm
11:00 am – 3:00 pm
Convention Center, Room 146B

This presentation moves beyond the basics of IACUC to address issues that may require special attention from the IACUC, including the role of IACUC as facilitator of research, conducting semi-annual program review and facility inspection, protocol approval monitoring and more. Participants will be able to pose questions to representatives of USDA, OLAW, and AAALAC. There is no charge for this session, but seating is limited, so pre-registration is encouraged. Contact: Alice Ra’anan at 301-634-7105 or araanan@the-aps.org.

Making Science News
http://www.the-aps.org/press/conference/eb04/sciencenews.htm
2:00 pm – 5:00 pm
Convention Center, Room 140A

The goal of this symposium is to familiarize scientists with how the media works. The ever expanding interest in scientific news is an opportunity to assist in public understanding of and public support for biomedical research. Helping scientists to take advantage of these opportunities is the aim of this symposium. A panel of three journalists will offer their insights into what makes science news and the best practices for getting scientific research covered. Contact: Stacy Brooks at 301-634-7253 or sbrooks@the-aps.org.

Sunday, April 18

International Scientific Collaboration in an Era of Heightened Security
12:30 pm - 2:30 pm
Convention Center, Room 201
Hear special guest speaker George H. Atkinson, Ph.D., Science and Technology Advisor to U.S. Secretary of State Colin Powell, address the important issue of international scientific collaboration in this post-9/11 era. He will discuss the effect of our nation's new policies on travel to and from scientific meetings in the United States and on the employment of foreign scientists, including the foreign postdoctoral fellows who are crucial to much of the important research conducted in many U.S. laboratories.

**The New CSR Review Process: An NIH Review**

1:00 pm – 2:30 pm  
Convention Center, Room 147A

This session will present an overview of the changes to Initial Review Groups at NIH’s Center for Scientific Review that are being implemented as a result of the recommendations of the Panel on Scientific Boundaries of Review.

**Monday, April 19**

**Scientific and Regulatory Challenges Involving Dietary Supplements and Botanical Products**

12:30 pm – 2:00 pm  
Convention Center, Room 143/AB

Confirmed Speakers:
- Lester Crawford, Acting Commissioner, Food and Drug Administration
- Paul Coates, Director, Office of Dietary Supplements, NIH
- Stephen Straus, Director, National Center for Complementary & Alternative Medicine, NIH.

Topics to be addressed include: how to promote a stronger scientific foundation at the FDA and the need to promote better health through better research; how new collaborations with NIH will help to improve our understanding of the underlying mechanisms of action and help to improve safety and efficacy of these products; research opportunities for the extramural community; and regulatory perspectives on the Dietary Supplement Health & Education Act of 1994 (DSHEA).

Contact: Jim Bernstein at 301.634-7062 or jbernstein@aspet.org

**Will You Still Fund Me Tomorrow? The Deficit, Bioterror, and the NIH Roadmap**

3:00 pm – 4:30 pm  
Washington Convention Center, Room 207B

Chair: Dr. W. Allan Walker, Harvard Medical School

Join NIH Director Elias Zerhouni, M.D. and NIDDK Director Allen Spiegel to address how a radically changing environment will impact NIH grantees in the coming years. Drs. Zerhouni and Spiegel will discuss the prospects for NIH funding in light of increasing federal budget deficits, the need for biodefense spending, and the NIH Roadmap. They will also address how the roadmap initiatives will complement or compete with investigator-initiated research and how the various institutes and centers will implement and plan for future Roadmap projects.

**Tuesday, April 20**

**Sustaining Integrative & Organ Systems Sciences: Problems, Opportunities, Solutions**

12:30 pm – 2:00 pm  
Convention Center, Room 143C

Chair: Dr. David B. Bylund, University of Nebraska

Confirmed Speakers:  
- Jerry Buccafusco, Medical College of Georgia;  
- Gerald Schaefer, Wil Research Laboratories, Inc.;  
- Steve Zeisel, University of North Carolina;  
- Irv Zucker, University of Nebraska;  
- Stanley J. Wiegand, Regeneron Pharmaceuticals, Inc.;  
- Peter Preusch, National Institutes of Health

The advent of molecular biology has produced a vast wealth of information on human health and disease. However, there has been a decrease in the number and ability of trained investigators – and students pursuing training and research – in the integrative and organ systems sciences. Science cannot effectively study disease or treatments for a disease simply by using isolated molecules, cells, or organs. Speakers will give their perspectives on the challenges and opportunities for enhancing the integrative & organ systems sciences by addressing its impact on both academic and industrial concerns.

Contact: Jim Bernstein at 301.634-7062 or jbernstein@aspet.org
Pharmacotherapy of Obesity: Targets and Tools for the 21st Century

Framing the problems for research in obesity and the role of NIH in progress toward solutions
Philip F. Smith, Ph.D., NIDDK, NIH

A clinical view of the obesity epidemic and current pharmacologic treatments
F. Xavier Pi-Sunyer, M.D., St. Luke’s/Roosevelt Hospital

The new neuroendocrinology of energy homeostasis
Michael W. Schwartz, M.D., University of Washington

The pharmacology of melanin concentrating hormone antagonists in the regulation of eating and body weight
Timothy J. Kowalski, Ph.D., Schering Plough Research Institute

Melanocortins as targets for anti-obesity agents
Russell Sheldon, Ph.D., Proctor and Gamble Pharmaceuticals

Molecular physiology of adipocyte signaling and lipolysis
Sheila Collins, Ph.D., Duke University Medical College

Fatty acid synthase inhibitors as therapeutic tools: Basic science and clinical outlook
Frank Kuhajda, M.D., Johns Hopkins University School of Medicine

Serotonergic mechanisms regulating eating and satiation
Kenny J. Simansky, Ph.D., Drexel University College of Medicine

Serotonergic 5-HT2c receptor agonists as novel therapeutic agents for obesity
Keith Miller, Ph.D., Bristol Myers Squibb

Peripheral peptidergic mechanisms regulating food intake
Timothy H. Moran, Ph.D., Johns Hopkins University School of Medicine

Peripheral peptidergic mechanisms regulating eating: Progress in pharmaceutical development
TBN

Friday, April 16, 2004
Washington, DC

The ASPET-Ray Fuller Symposium Series

To Register: www.aspet.org/public/meetings/rf7_regform_int.pdf
Molecular Pharmacology Online Manuscript System Launched

On March 1, Molecular Pharmacology’s online manuscript submission, tracking, and peer-review system launched. The system is accessible from a link on the journal web site, molpharm.aspetjournals.org. The Molecular Pharmacology system is from Bench>Press, a product of Stanford University’s HighWire Press.

Those who have used JPET’s version of Bench>Press will find the Molecular Pharmacology version quite similar. The latter system was customized to Molecular Pharmacology’s workflow. The screens used by authors and reviewers will be familiar. Most of the differences are behind the scenes.

The first manuscript submitted through Bench>Press was entered by a prospective author about an hour after the system went live. Others quickly followed. All new manuscripts will be processed using Bench>Press. Those submitted prior to March 1 will go through the old manual system, including revisions to previously submitted papers.

All Bench>Press users are assigned roles—author, editor, associate editor, reviewer, or staff. As a manuscript goes through the review process, access to the paper and related information is provided as appropriate to the role a person plays. Manuscripts go through a number of queues, each a stage in the review process. When all appropriate tasks for a queue are completed, the manuscript automatically moves to the next queue. Each progression triggers automated email messages to notify the appropriate person that an action is needed. Reminder messages are sent automatically when the action has not been completed within a designated time frame.

Jill Filler, ASPET’s Managing Editor, worked closely with HighWire Press to design and implement the system. Debbie Ellis and Rhonda Frankenfield, Editorial Coordinators, provided detailed information on workflow to assure that manuscripts are processed according to the journal’s procedures and policies. They also did extensive testing of the system once its development site was available, playing the roles of author, editor, associate editor, reviewer, and staff.

Once a paper is accepted through Bench>Press, it will be published in manuscript form online ahead of print, generally 6 to 10 weeks ahead of publication in an issue. These “Fast Forward” articles will be viewable from the journal web site. Because citation information such as volume and page numbers will not yet be available, Fast Forward articles are citable by their Digital Object Identifier or DOI.

Testing and final adjustments are being made to a version of Bench>Press for Drug Metabolism and Disposition. As for Molecular Pharmacology, the system is being customized to match DMD’s workflow. The DMD system will be activated at the end of March. Watch the journal’s web site for a link to DMD B>P!

We’re almost there...

But we need your help to complete ASPET’s collection of back issues for scanning. Before we can start putting back issues of ASPET’s journals online, we need complete sets. The following issues are missing:

Molecular Pharmacology
- Vol. 10 (all), 1974
- Vol. 12, nos. 2-6, 1976
- Vol. 13 (all), 1977
- Vol. 14 (all), 1978

Drug Metabolism and Disposition
- Vol. 20, no. 1, 1992
- Vol. 21, nos. 2-6, 1993
- Vol. 23, no. 4, 1995

Copies must be “de-spined” for scanning and cannot be returned.

If you can donate any of these issues, please contact Rich Dodenhoff, Journals Director, at rdodenhoff@aspet.org or call 301-634-7997. ASPET will pay shipping costs.
NIGMS RFA to Support Training of Integrative Whole Organ Biologists

The NIGMS advisory council approved a RFA that will solicit proposals for a summer short course to provide training in integrative and organ systems pharmacology for FY’05, ’06, and ’07. The R25 educational project grant would set aside $500,000 in the first year. It is expected that the RFA will be published in late March and appear on the NIGMS and ASPET web sites. A summary of the proposed NIGMS RFA can be viewed at http://www.aspet.org/public/public_affairs/NIGMS_IOSS_rfa.html.

Pharmacogenetics Research Network

The next open competition of the Pharmacogenetics Research Network (PGRN) and Knowledge Base (PharmGKB) will take place in 2004. The request for applications is at http://grants.nih.gov/grants/guide/rfa-files/RFA-GM-04-002.html.

Congress May Mandate Adverse Event Reporting for Dietary Supplements

With FDA’s recent announcement that it will ban dietary supplements containing ephedra, Congress may mandate adverse event reporting for dietary supplements. There is likely to be a court challenge to FDA’s ruling with the charge that FDA does not have the scientific evidence required by law to ban ephedra. FDA has traditionally not taken any stance in support of legislation to change dietary supplement law, but that may change with the latest ephedra ruling. A final rule by FDA justifying its rationale for the ban is expected soon.

Veterinarians in Biomedical Research

A National Research Council publication, "National Need and Priorities for Veterinarians in Biomedical Research,” identifies various factors that contribute to creating an unfulfilled need for veterinarians in the biomedical research workforce, including an increase in the number of NIH grants utilizing animals and the burgeoning use of transgenic rodents, without a comparable change in the supply of appropriately-trained veterinarians. The Committee on Increasing Veterinary Involvement in Biomedical Research developed strategies for recruiting more veterinarians into careers in biomedical research. The report can be ordered online at http://books.nap.edu/catalog/10878.html. ASPET supported this study, along with the American College for Laboratory Animal Medicine, The American Veterinary Medical Association, GlaxoSmithKline, Merck and Co., and Pfizer.

Chemistry and Biology Symposium

NIGMS is co-sponsoring a symposium on "Chemistry and Biology: Partners in Decoding the Genome." It will be held on March 15-16, 2004, in the Natcher Conference Center on the NIH campus. The meeting Web site is at http://genome.gov/11008534.

NCCAM Invites Input for Strategic Planning

The National Center for Complementary and Alternative Medicine (NCCAM) is starting its second 5-year strategic planning effort. The year-long planning effort will involve the public, researchers, health care professionals, NCCAM staff, and others with an interest in research on complementary and alternative medicine (CAM). For information on upcoming strategic planning stakeholder forums and input into the strategic planning process visit: http://nccam.nih.gov/news/2004/013004.htm.

Botanical Research Centers RFA

A request for applications has been issued to establish new Dietary Supplement Research Centers to study botanicals. The goals of these centers will be to promote interdisciplinary collaborative research into botanicals and to conduct research with high potential to be translated into practical benefits for human health. View: http://nccam.nih.gov/research/announcements/rfa/index.htm#active.

FY’05 NIH Funding

The research and patient advocacy communities are advocating a 10% increase above the FY’04 level. The FASEB consensus conference on Federal Funding for Biomedical and Related Life Sciences Research can be viewed at http://www.faseb.org.
Division Election Results for 2004

Division for Behavioral Pharmacology

Alice M. Young
Chair-Elect
Elise M. Weerts
Secretary/Treasurer-Elect

Division for Cardiovascular Pharmacology

Nancy J. Rusch
Chair-Elect
Debra I. Diz
Secretary/Treasurer-Elect

Division for Drug Metabolism

David S. Riddick
Chair-Elect
Xinxin Ding
Secretary/Treasurer-Elect

Division for Molecular Pharmacology

Diane M. Perez
Chair-Elect
T. J. Murphy
Secretary/Treasurer-Elect

Division for Neuropharmacology

David R. Sibley
Chair-Elect
Sandra P. Welch
Secretary/Treasurer-Elect

Division for Toxicology

Marc W. Fariss
Chair-Elect
Jack A. Hinson
Secretary/Treasurer-Elect
The Bernard B. Brodie Award Fund – Progress Report

As a brief history, the Bernard B. Brodie Award in Drug Metabolism was created in 1977 by the Drug Metabolism Division and initially funded by CIBA-Geigy. CIBA-Geigy withdrew its sponsorship in 1995. After 2-3 years of sponsorship by Dow-Elanco and then SmithKline Beecham, continued sponsorship was suspended, and it became a struggle on the part of ASPET Council to identify a donor every other year. In 2001, the Council decided to seek endowment funds for each of the society's awards. Given the history of the Brodie award, it charged the Drug Metabolism Division with the responsibility of securing the necessary endowment funds, which it estimated to be $60,000. ASPET will continue to support the award only through 2004. A more complete description of the award, past recipients, and a link to more information about the current fund raising effort, including a list of donors, can be accessed through the ASPET web page (select Awards and Fellowships).

The highly prestigious Bernard B. Brodie Award is the only award honoring investigators who have made significant, lifetime contributions to our knowledge of drug metabolism and disposition. The Drug Metabolism Division’s Award Development Committee (Ron Hines, Bettie Sue Masters, Ron Estabrook, and Drag Anders) initially solicited funds from the membership of the Division and was successful in raising approximately $16,000. Subsequent requests for matching funds from the pharmaceutical industry resulted in the attainment of our current total, $34,028. Appeals are currently in progress to reach the final goal of $60,000 by the end of this year. If you think you could help with this effort by making key contacts, please send a note to Ron Hines at the Medical College of Wisconsin (rhines@mail.mcw.edu). Because ASPET is a 501 (C) (3) tax-exempt educational institution, any contributions made to the Brodie Award are tax deductible.

MEMBERS IN THE NEWS

Kenneth A. Jacobson is the winner of the 2003 Hillebrand Prize from the Chemical Society of Washington, a section of the American Chemical Society. Dr. Jacobson is Chief of the Molecular Recognition Section in the Laboratory of Bioorganic Chemistry of the National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK) of NIH. In 2003 he was appointed as the first Director of the new Chemical Biology Core Facility in NIDDK. He is also an Adjunct Professor at the Uniformed Services University of the Health Sciences. Dr. Jacobson’s research interests lie in the area of the structure and pharmacology of G protein-coupled receptors, particularly those for adenosine and its nucleotides.

The Hillebrand Prize is awarded for original contributions to chemistry by members of the Chemical Society of Washington. It is named for William F. Hillebrand (1853-1925) who, for many years, was chair of the Supervisory Committee on Standard Methods of Analysis of the American Chemical Society.

Garret A. Fitzgerald is the winner of the PhRMA Foundation 2004 Award in Excellence of Clinical Pharmacology. Dr. Fitzgerald is Chair of the Department of Pharmacology at the University of Pennsylvania School of Medicine. His research was fundamental in gaining an understanding of the role that arachidonic acid and its metabolites play in inflammation and included working out the mechanism of the effects of aspirin on platelet function. His recent research has focused on the tissue selectivity of COX-1 and COX-2.

The PhRMA Foundation Awards in Excellence are given annually to investigators who received a Foundation grant at the outset of their careers and have gone on to distinguish themselves through their scientific or academic achievements.
W. Leigh Thompson was honored by the FDA with the receipt of the Commissioner’s Special Citation for Multiple Innovative Contributions to Public Health and Wellbeing. Dr. Thompson has made significant contributions to medical care, drug development, and public health through collaborative drug development innovations with the FDA. He developed clinical trial reference ranges adopted for broad use by the FDA, and he has consulted with the Agency on drug and device development, global regulatory strategies, health informatics, strategic planning, research management, and process re-engineering. Dr. Thompson is currently President and CEO of Profound Quality Resources, Ltd.

Arthur J. Atkinson, Jr., Senior Advisor in Clinical Pharmacology to the Director of the NIH Clinical Center, will receive the 2004 Henry W. Elliot Distinguished Service Award from the American Society for Clinical Pharmacology and Therapeutics at its annual meeting in Miami, March 24-27, 2004. The Elliot Award is given to a member of ASCPT to recognize exceptional service to the Society.

Meindert Danhof, Head of the Division of Pharmacology at the Leiden/Amsterdam Center for Drug Research, will receive the 2004 Rawls-Palmer Progress in Medicine Lecture Award from the American Society for Clinical Pharmacology and Therapeutics at its annual meeting. The Rawls-Palmer Award was established to recognize mid-career clinical pharmacologists who facilitate the delivery of modern research results to patients.

Contributors in 2004

B.B. Brodie Award
John Cashman
Bettie Sue Masters
Mary Vore

P.B. Dews Award
Alice Young

Joseph P. Buckley
David Clarke

Thomas F. Burks
Theodore M. Brody
James V. Bruckner
Mark A. Osinski
Kenneth D. Wild
Paula Witt-Endeby

Keith F. Killam, Jr.
Theodore Brody
John Bunker
Kelvin Gee

John P. Perkins
Barton Kamen

Frank G. Standaert
Theodore M. Brody
Donald Franz

A.E. Takemori
Michael Ahlijanian
Theodore M. Brody
Earl Dunham
Valerie Takemori
Kenneth Wild

Sustaining Members
Craig Beeson
Thomas Blaszkowski
Theresa Brancheck
Hugh Burford
Stewart Ehrreich
Jeffrey Fedan
Gerald Gianutsos
Giancarlo Guideri
John McCullough
Raymond Novak
Mark Perrone
Markus Peter
Walter Prozialeck
Ralph Purdy
Paula Stern
Richard Vulliet
Francis White

Members Fund
Elaine Sanders-Bush
George Van Rossum

Young Scientist Fund
Stewart Ehrreich
Alvin Gold
Joyce Goldstein
Astrid Parenti
Paola Petrillo
Xiang Wang

Corporate Contributors to EB’04 Activities
Abbott Laboratories
Bayer
Bristol-Myers Squibb
Dov Pharmaceutical
Drexel University
Eli Lilly and Company
Merck Research Laboratories
Wyeth Research

A Publication of the American Society for Pharmacology and Experimental Therapeutics - ASPET

Volume 46 Number 1, 2004
The ASPET Office moved into its new quarters in FASEB’s New East Wing over the President’s Day weekend. Staff quickly unpacked and settled in with minimal disruption to business. Mailing address, phone numbers and email remain the same as they were in the old quarters.

ASPET’s journals and books packed up and ready to move (left) and in their new location in the new ASPET conference room and library (right). It was no small feat packing and unpacking 96 years worth of JPETs, 38 years of Molecular Pharmacology, 30 years of DMD, 54 years of Pharmacological Reviews, plus The Pharmacologist, Rational Drug Therapy, reference books and other archival materials.

ASPET’s Journals Office all packed and ready to move (left); Moved, but not yet unpacked (center); and Settled in and (almost) fully operational (right).

In its new space, ASPET acquired several new features that have been greatly needed and are appreciated by both staff and visitors. The new Pantry area (left) provides a place not only for staff to eat, but also for the caterers to set up coffee and lunches for committee meetings without interrupting the meeting in the conference room. The new workroom (center) gives staff much needed storage and work space to do projects without having to disrupt their desks or the conference room. The reception area (right) provides an attractive space for visitors to be greeted.
ASPET Journals Office Hires New Editorial Assistant

Dan Collinge, B.A., Editorial Assistant

Dan joined ASPET in January of 2004 as an Editorial Assistant. A recent graduate of The Catholic University of America in Washington, D.C., Dan is looking forward to putting his background in English to use in a variety of capacities. He spends most of his time working with the Journal of Pharmacology and Experimental Therapeutics, helping to ensure that new manuscripts are processed, reviewed on time, revised correctly, and published on the Internet. He will shortly assume similar responsibilities for Molecular Pharmacology as well. Dan’s prior work experience includes a temporary appointment at the U.S. General Accounting Office and an Editorial Internship in the Office of Communications at Mount St. Mary’s College, MD.

NEW MEMBERS

REGULAR MEMBERS

Abraham, S. Thomas, Campbell University School of Pharmacy, Dept of Pharmaceutical Sciences
Bai, Aijing, Medical University of South Carolina, Dept of Pathology & Lab Medicine
Beeson, Craig, Medical University of South Carolina, Dept of Pharmaceutical Sciences
Brady, Joseph, Johns Hopkins University, Bayview Medical Center
Chiou, Lih-Chu, National Taiwan University, Dept of Pharmacology
Desai, Rajeev, NIH/National Inst. on Drug Abuse
Dunaway, George, Southern Illinois University School of Med, Dept of Pharmacology
Fitch, Richard, Indiana State University, Dept of Chemistry
Lemmonds, Charlotte, GlaxoSmithKline, Smoking Control
Mackenzie, Peter, Flinders University School of Medicine, Dept Clinical Pharmacology
Murali, Badanadka, University of Louisiana, Dept of Toxicology
Murray, Katherine, University of California, Dept of Pharmacology
Nishihara, Hiroshi, University of California, Dept of Pharmacology
Peart, Jason, Medical College of Wisconsin, Dept of Pharmacology & Toxicology
Rabinowitz, Joshua, Alexza Molecular Delivery Corp
Scharfman, Helen, Helen Hayes Hospital, Ctr. for Neural Recovery and Rehab Rsch
Schaum, Robert, Pfizer Global Research & Development
Siehler, Sandra, Novartis Institutes for Biomedical Rsch, Discovery Technologies
Strobl, Jeannine, West Virginia University Medical Center, Dept of Biochemistry & Molecular Pharmacology
Thirunavukkarasu, Chinnasamy, University of Pittsburgh, Thomas E. Starzi Transplantation Inst.
Tolle, Virginie, Oregon Health and Science University, Vollum Institute
Udwadia, B.P., Sun Pharma Advanced Research Center

AFFILIATE MEMBERS

Fang, Cheng, Wadsworth Center, New York State Dept of Health
Yetik-Anacak, Gunay, Medical College of Georgia, Vascular Biology Center

UNDERGRADUATE STUDENT MEMBERS

Bingham, Taiese, University of Maryland
Bryant, Xavier, Clark Atlanta University
Hardy, Klarissa, Jackson State University
Mapp, Oni, University of Maryland

STAFF NEWS, cont.
GRADUATE STUDENT MEMBERS

Beckel, Jonathan, University of Pittsburgh, Dept of Pharmacology
Brevig, Holly, University of Michigan, Dept of Pharmacology
Chen, Shuzhen, University of Florida College of Medicine, Dept of Pharmacology and Therapeutics
Chilakapati, Jaya, University of Louisiana School of Pharmacy, Dept of Toxicology
D'Agostino, Jaime, SUNY At Albany, School of Public Health
De, Ananya, University of Minnesota, Dept of Pharmacology
Del Valle Mojica, Lisa, University of Puerto Rico School of Med, Dept of Pharmacology
Dubinion, John, University of Pittsburgh School of Medicine, Center for Clinical Pharmacology
Duckworth, Edward, University of South Florida, Dept of Pharmacology
Figueroa, Katherine, University of California, Dept of Pharmacology
Giner, Isabel, University of Valencia, Dept of Pharmacology
Gonzalez, Anjelica, Baylor College of Medicine, Dept of Structural & Comp Biology
Gorovoy, Matvey, University of Illinois, Dept of Pharmacology
Hamel, Michelle, University of South Florida, Dept of Pharmacology
Hoffmann, Sarah, Louisiana State University HSC, Dept of Pharmacology
Hote, Prachi, University of Louisville, Dept of Pharmacology & Toxicology
Hudson, Holly, University of Colorado HSC, Dept of Pharmacology
Jia, Zhe, University of Arizona College of Pharmacy, Dept of Pharmacology & Toxicology
Kassel, Karen, University of Nebraska Medical Center, Dept of Pharmacology
Kell, Angela, University of Minnesota, Dept of Pharmacology
Kennedy, Wentworth, Loma Linda University, Dept of Physiology and Pharmacology
Kong, Xiaoying, Northeastern Ohio University College of Med, Dept of Biochemistry & Molecular Pathphysiology
Korrapati, Midhun, University of Louisiana College of Hlth Sciences, Dept of Toxicology
Lan, Hongxiang, Oregon Health & Science University, Dept of Pharmacology
Lavicky, Megan, University of Nebraska Medical Center, Dept of Pharmacology
Li, Tiangang, Northeastern Ohio University College of Med, Dept of Biochemistry
Linder, Aurea, Medical College of Georgia, Dept of Physiology
Liu, Reijun, Drexel University College of Medicine, Dept of Pharmacology
Liu, Yun, Oklahoma University HSC, College of Pharmacy
Luyendyk, James, Michigan State University, Dept of Pharmacology & Toxicology
Marriott, Andrea, Georgetown University, Dept of Pharmacology
Martino, Leslie, Louisiana State University, Dept of Biological Psychology
Mayer, Joanne, University of South Florida, Dept of Microbiology
Miller, Rebecca, University of Missouri, Dept of Pharmacology
Modi, Tanvi, University of Louisville, Dept of Pharmacology & Toxicology
Murphree, Lauren, University of Virginia, Dept of Pharmacology
Naugle, Jennifer, Northeastern Ohio University College of Med, Dept of Physiology and Pharmacology
Obregon, Demian, Tulane University HSC, Dept of Pharmacology
Pfeiffer, Emily, University of Minnesota, Dept of Pharmacology
Razmara, Ali, University of California, Dept of Pharmacology
Sabbisetti, Venkata, University of Louisiana, Dept of Pharmacology
Sanjay, Kadnur, L.M. College of Pharmacy, Dept of Pharmacology
Sengupta, Rajarshi, University of South Florida, Dept of Pharmacology
Tawfik, Vivianne, Dartmouth Medical School, Dept of Pharmacology
Tiwari, Manish, University of Arkansas Medical Sciences, Dept of Pharmacology & Toxicology
Wang, Fei, University of Florida College of Medicine, Dept of Pharmacology & Therapeutics
Weng, Yan, SUNY School of Public Hlth, Wadsworth Center
Whitley, Alex, Medical University of South Carolina, Dept of Pharmacology
Yusof, Mozow, University of Missouri, Dept of Meical Pharmacology & Physiology
Zefirova, Julia, Kazan State Medical University, Dept of Pharmacology
Walter F. Riker, Jr., M.D.
1917 – 2004

Dr. Walter F. Riker, Jr., The Revlon Professor Emeritus of Pharmacology at Weill-Cornell Medical College, and a distinguished educator, research scientist, and physician died Friday, February 20, 2004, at New York Hospital. He was 87, having spent his entire 53-year scientific career at the eastside Cornell medical complex. He won its Alumnus of Distinction award in 1981.

Born in the Bronx, Dr. Riker was appointed chairman of the College’s pharmacology department in 1956, which he subsequently led for 27 years. In recognition of his teaching skills, his medical students awarded him Excellence in Teaching Awards in each of three decades. While educating thousands of physicians he also conducted breakthrough research on how nerves control muscle function. Beginning in the early 1950’s his creative vision was to anticipate the future use of drugs as tools to understanding nerve cell physiology. His findings led to the greater understanding and diagnosis of neuromuscular diseases, such as myasthenia gravis, and the use of modern muscle relaxants for surgical procedures.

Dr. Riker’s influence on American pharmacology was significant, producing thirteen heads of university pharmacology departments, an FDA Commissioner, countless physician researchers and medical practitioners who took with them his principled approach to the use of drugs to better treat their patients. In 1968 he helped create and implement the first minority education program at Cornell Medical College. Dr. Riker was widely recognized as one of the world’s experts on the neuromuscular junction, and as a dean of American twentieth century pharmacology. His philosophies, teachings and lifelong research helped integrate pharmacology into medical schools’ clinical curricula.

Although much of his life’s work focused on academia, Dr. Riker was sought after by industry, for example as a board member of Richardson-Vicks, Inc. and as an advisor to The Pharmaceutical Manufacturer’s Association and the Sterling-Winthrop Research Institute.

In 1973 NFL Commissioner Pete Rozelle appointed Dr. Riker its drug advisor to pro football, the first such post in NFL history. His eleven years of service to the League was prescient in recognizing the importance of institutionalized tracking of prescription drugs by professional sports teams. His admonitions at that time concerning the medical consequences of steroid use by athletes, drug accountability and control are now commonly accepted.

Walter Franklyn Riker, Jr. was born in New York City on March 8, 1916. He graduated from De Witt Clinton High School in the Bronx to which he later became a distinguished alumnus. In 1939 he earned his BA at Columbia University and an MD at Cornell Medical College in 1943. After service in the US Army Chemical Warfare Service, and medical training in New York, he ascended to professorships at Cornell and visiting positions in Japan, The University of Kansas, The Roche Institute for Molecular Biology, and Morehouse College. In 1960 his peers elected him to Alpha Omega Alpha, the honor medical society. Dr. Riker was made the first American member of the Japanese Society of Pharmacology in 1972 along with Nobel Laureate Julius Axelrod. His awards include The Torald Sollmann Award, the Oscar B. Hunter and John J. Abel Awards in pharmacology, and the Maurice Greenberg Distinguished Service Award to Cornell. The Medical College of Ohio awarded him its honorary Doctor of Science degree in 1980. Dr. Riker was a charter member of the Irma T. Hirschl Trust dedicated to the support of outstanding medical scientists in New York City medical schools. He was active in the American Society for Pharmacology and Experimental Therapeutics, serving in various editorial positions including Chairman and Trustee of Publications.

Dr. Riker is survived by his wife of 62 years, Virginia; three sons, Dr. Donald Kay Riker, a pharmacologist, Walter F. Riker III, and Wayne S. Riker; his brother Dr. William Kay Riker, also an emeritus chairman of pharmacology; and his sister Virginia R. Huebner; seven grandchildren and two great-grandchildren.

In lieu of flowers, donations can be made to the Walter and Virginia Riker Scholarship Fund for Needy Students, The Weill-Cornell College of Medicine, Alumni Relations Office, Box 61, 1300 York Avenue, New York, New York, 10021.

Note: Dr. Riker wrote this obituary himself. It was edited by his family for the dates and events related to his death.
Jean M. Devlin
1937 – 2003

On July 2, 2003, Jean M. Devlin passed away at the age of 66, following a long battle with cancer. She is survived by her brother, Michael McDonald, and several nephews.

Jean was born and, for the most part, educated in London, England. She received part of her secondary education in France, an experience that left her with an enduring affection for that country and its culture. She went on to obtain a Bachelor of Sciences degree at the University of London and thereafter conducted research in pharmacology at Queen Charlotte's Hospital in London.

In 1967, she emigrated to the United States and accepted a position in the Pharmacology Department at Harvard Medical School where she designed, performed and supervised experiments for medical students.

After two years at Harvard, she moved to the University of California at Santa Barbara (UCSB) where she was associated with several departments over the next 25 years. During her stay, UCSB established the first undergraduate major in pharmacology, and she was instrumental in its successful development: she designed experiments and supervised the laboratory component of the course; she single-handedly raised funds from industry to create international exchange programs with universities in the U.K., France, Switzerland, and Italy; and she launched innovative internship programs with the pharmaceutical and biotechnology industries, all of which provided her students with a unique, broadly based and enriching experience. The program achieved international recognition and served as a model for similar initiatives at other institutions. For her contributions, she was elected to the American Society for Pharmacology and Experimental Therapeutics.

In 1994 she was recruited to the State University of New York at Stony Brook as Director of the Undergraduate Pharmacology Program, the second of its kind in the U.S. Here, she replicated her numerous previous activities and accomplishments at Santa Barbara and mounted a particularly successful international exchange program, which received the National Science Foundation's Award for Educational Innovation in 1999. In 2000, SUNY-Stony Brook established an endowment to support a prize in her honor - the Jean M. Devlin Award – which is awarded to the graduating student showing the greatest promise as a future contributor to pharmacology.

In 2000, Jean moved to the Rockefeller University in New York as its first Director of Educational Affairs. In this position her responsibilities included recruiting graduate students, administering the graduate student program, organizing the university’s postdoctoral association, and directing the program for Summer Undergraduate Research Fellows, some of whom later became candidates for the graduate program. Her impact on Rockefeller was, tragically, abbreviated by the onset of her terminal illness.

Jean Devlin was a remarkable person. She had a firmly rooted set of values and a strong sense of fairness and integrity. She was sympathetic and helpful to her students, and, in return, she expected and demanded responsible behavior and performance. She had amazing, apparently inexhaustible, energy that enabled her to perform her professional work at a high level of intensity and, in addition, to serve on numerous boards of volunteer organizations, e.g., as Vice-President and Director of the Rudi Schulte Research Institute in Santa Barbara. She radiated an infectious, galvanizing cheerfulness and optimism, which she retained to the end. She was unfailingly generous, loyal and supportive of friends, associates, colleagues and students. She lived life to the fullest -- dressing elegantly, traveling widely, often vacationing in France, enjoying friendships in many places, laughing easily and often.

Those who knew her will never forget her.

Contributions to honor her memory may be made payable to the Ms. Jean M. Devlin Endowment Fund, Department of Pharmacology, Stony Brook University, BST-8-140, Stony Brook, New York, 11794-8651.

Prepared by Ed Reich

ASPET notes with sympathy the passing of the following members:

Bernard V. Franko  Walter F. Riker
Charles W. Gowdey  Edward B. Truitt, Jr.
Arthur E. Heming

A Publication of the American Society for Pharmacology and Experimental Therapeutics - ASPET

Volume 46 Number 1, 2004
Edward Byrd Truitt, Jr., Ph.D.
1922-2004

Dr. Edward Truitt, Jr., a charter faculty member at Northeastern Ohio Universities College of Medicine and its first chairman of Pharmacology, died on January 6, 2004, from stroke complications at Akron City Hospital, Ohio. He was a World War II Navy veteran, having started his service as 5th officer on LSM36 and finishing as commander of a Landing Ship Medium.

He was born in Norfolk, VA on August 23, 1922. He earned his B.S in Pharmacy from Medical College of Virginia in 1943 and his Ph.D. in Pharmacology from University of Maryland in 1950. He held professorships in Pharmacology at Bowman Gray School of Medicine at Wake Forest University, University of Maryland School of Medicine, The Ohio State University College of Medicine and George Washington University School of Medicine. At Northeastern Ohio Universities College of Medicine, Dr. Truitt recruited Pharmacology faculty and staff, supervised development of the course in Medical Pharmacology and participated in the successful accreditation process. He also organized and headed Institutional Review Boards and subcommittees at Northeastern Ohio Universities College of Medicine. At the national level, he served on the NIH Review Panel, on the editorial boards of various scientific journals and as a consultant for a number of major pharmaceutical firms. He authored and co-authored numerous original research papers and review and book chapters. He was a member of several professional societies and was actively involved at the local and national level on Alcoholism and Drug Abuse Task Forces/ Councils.

Ed’s long research career in the field of alcoholism began at the University of Maryland soon after his postdoctoral tenure at A.H. Robins Co. At A.H. Robins Co, Ed directed the developmental pharmacology of the skeletal muscle relaxant, methocarbamol, and other drugs while a faculty member at Bowman Gray School of Medicine. His initial work at the University of Maryland involved a shared initial pharmacological discovery of the convulsant antidepressant, fluorothyl, and several inhalant anesthetic agents as well as extensive studies on the metabolism and action of salicylate drugs. His first important research contribution to the field of alcoholism was the early identification of the actions of acetaldehyde, an ethanol metabolite, on cell mitochondria and biogenic amine neurotransmitter functions. This was followed by his pioneering studies, conducted at Battelle-Columbus Laboratories, looking at chronic changes in alcohol and biogenic amine metabolism and their interaction in animals and alcoholics. These studies were the first to recognize the role of increased levels of acetaldehyde in the alcoholic patient and to examine the effect of this increase in altering catecholamine metabolism by competition at the aldehyde degradation step. This provocative work led to the proposition that aberrant alkaloidal biogenic amines may be produced in the brain such as the tetrahydroisoquinolines and tetrahydrobetalcarbolines. His most recent research focused on lithium chloride as a potential alcoholism therapy as well as on the role of abnormalities in alcohol metabolism, particularly the role of acetaldehyde in establishing a hereditary link for alcoholism. In this context, he recently developed an improved clinical test for acetaldehyde in blood, which is bound to hemoglobin as an acetaldehyde-hemoglobin adduct and was awarded a technology patent on the process of the isolation of the acetaldehyde-hemoglobin adduct.

In addition to his alcohol research, Ed also conducted research on several other psychoactive drugs. At Battelle-Columbus Laboratories, he initiated and directed a large multidisciplinary project on smoke analysis and metabolism of the psychoactive components of marijuana. This work led to the discovery of the psychoactive metabolite, 11-hydroxy-delta-9, tetrahydrocannabinol. His research evaluated the behavioral effects of components of marijuana smoke and the effects of marijuana on brain biogenic amine functions. At the University of Maryland, his early work on psychoactive agents was directed at understanding the ethno-pharmacology of myristicin from nutmeg and in case of amphetamine -- its stereotypical behavioral actions.

Dr. Truitt was also an excellent teacher as he challenged his students intellectually. He was a father figure for both graduate and medical students and was praise worthy of their accomplishments. He mentored several graduate students and postdoctoral fellows and was generous and kind to his students, colleagues and friends alike. In addition to his academic career, Ed was actively involved with his church community to improve the living conditions of the world. He will be immensely missed by his colleagues, friends and family. He is survived by his wife, Jessie; his two children, Elizabeth Pottorff and Edward; two stepchildren, Kari Govan and Bill Dueser; and seven grand children.

Prepared by Pushpa V. Thadani
IUPHAR Web Sites for Receptor and Ion Channel Annotation and Classification Now Available

The International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR) comprises 18 of the world’s experts and runs 50 subcommittees of the world’s experts in a given field. NC-IUPHAR has the mission of:

1. Issuing guidelines for receptor and ion channel classification,
2. Classifying the major receptor and ion channel systems,
3. Introducing a Receptor Code to aid classification,
4. Facilitating the interface between discovery of new sequences from the Human Genome Project and designation of the derived proteins as functional receptors and ion channels.

NC-IUPHAR has now established and will maintain a receptor database with a list of many of the receptor classes freely available on the world-wide web to all scientists. Receptor classifications will become available as they are finished. A second web site for voltage-gated ion channels has also been established. The chairman of the database committee, Sir Colin Dollery and Professor Tony Harmar, have interfaced with the European Bioinformatics Institute (EBI), for the voltage gated ion channel site (http://www.iuphar-db.org/iuphar-ic) and for receptor classification (http://www.iuphar-db.org/iuphar-rd), where the chapters of classification, and their supporting data tables are freely available. The receptor database is a fully interactive database, whereas, for the present, the ion channel database is composed of downloadable pdf files. The literature citation of the voltage–gated ion channel data will be via published references in Pharmacological Reviews.

For voltage-gated ion channels, a new classification is outlined which resolves many of the controversies in the field. Rationalisation of the classification of voltage-gated ion channels has been needed for some time. The schemes presented in this new classification represent the work of several subcommittees, coordinated by Professor William Catterall. The classification of sodium (Na, 1.1-1.9) and calcium channels (Ca, 1.1-1.4; Ca, 2.1-2.3; CA, 31.-3.3) follows the scheme previously advanced for potassium channels (Kv, K, Kca, Ksp, Ks) by Chandy and Gutman (1993). This new database also revises and updates the classification of potassium channels. Classification of cyclic nucleotide-modulated channels and transient receptor potential channels follows the same general guidelines.

Thus these new web sites include classifications of two of the most widespread groups of gene products from the human genome, with many physiological and pharmacological implications. Data tables for each gene product, listing the molecular information, electrophysiological properties, channel distribution and pharmacology are also included.

Using these new web-based interactive sites the NC-IUPHAR project will be able to be more proactive, maintaining up-to-date lists of many of the receptors in the human genome and curating the functional data. This is obviously possible only with the help of multiple subcommittees, where motivated members of the scientific community voluntarily enlist in the task of functionally annotating the receptor and ion channel sequences in the human genome. Members of the scientific community are very welcome to help NC-IUPHAR in this mission.

The receptor web site will progressively enlarge to cover all classes of receptors and will also make available articles on receptor classification. Construction of this web site has been supported by an important educational grant from Incyte Corporation. Activities of NC-IUPHAR have been supported by educational grants from Servier and Wyeth.

Submitted by: Michael Spedding, Chair, NC-IUPHAR
Sir Colin Dollery, Chair, Database Committee
Sue Duckles, Secretary General, IUPHAR
Paul Vanhoutte, President, IUPHAR

Receptor Classification Site http://www.iuphar-db.org/iuphar-rd
Voltage-gated Ion Channel Site http://www.iuphar-db.org/iuphar-ic
The National Cancer Institute (NCI), NIH, is making available specific inhibitory monoclonal antibodies (Mabs) to human cytochrome P450 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2C family, 2D6, 2E1, and 3A4/5. Some immuno-blotting Mabs are also available.

Requests for specific Mabs and a Material Transfer Agreement (MTA) should be addressed to:

Ann Pace, NCI
e-mail: pacea@mail.nih.gov

Larger quantities of the Mabs can be obtained by License from the Office of Technology Transfer (OTT) by contacting:

Fatima Sayyid
e-mail: Sayyidf@mail.nih.gov

Submit your manuscript today at
Molpharm.aspetjournals.org
4th International Symposium of Nucleosides and Nucleotides

June 6-9

William C. Friday Center
University of North Carolina
Chapel Hill, North Carolina, USA

Opening Lecture
Geoffrey Burnstock
Royal Free and University College Medical School, London
Overview of nucleoside/nucleotide signaling

Keynote Speaker
Robert J. Lefkowitz
Duke University
Seven Transmembrane-Spanning Receptors

Plenary Speakers
George Dubyak - Mechanisms of nucleotide release
Bertil Fredholm - Adenosine receptors
Christian Gachet - Regulation of platelet physiology by ADP
Alan North - P2X receptors
Simon Robson - Animal models of nucleotide metabolizing enzymes
Richard Boucher - Nucleotides/nucleosides in airway physiology

Symposia Topics
Platelets • Adenosine • Inflammation and Tissue Protection • Cardiovascular • Epithelia • Chemistry and Therapeutics • Release of Nucleotides • Metabolism and Transport • New Topics in Purine Signaling • P2Y Receptors • P2X Receptors • Channels and Pain

Active Poster Sessions Each Day

www.purines.org
The CPT2004 Congress will present the cutting edge of Clinical Pharmacology and Therapeutics. It is being held in Brisbane – one of the world’s leading, most accessible and hospitable meeting destinations, and the gateway to Australia’s premier tourist region, including the Great Barrier Reef, Whitsunday Islands and lush rainforests.

The Congress will feature:
- Invited plenary and symposium speakers
- A program organised in four parallel streams – Medicines & Society, Drug Discovery, Development & Disposition, Therapeutic Horizons and Late Breaking News
- Contributed poster presentations
- A comprehensive industry exhibition
- An exciting array of sponsored evening symposia
- Special education sessions and workshops including a Foundations of Clinical Pharmacology series running throughout the week
- Social program. Delegates and their accompanying guests will have many opportunities to meet socially and to renew or develop friendships - magnificent venues, fine wines, delicious food and a relaxed atmosphere.

Registration
An electronic Registration Brochure and Call for Abstracts are available on the Congress Website.

Registration and abstract submission will only be available online at www.cpt2004.com

THE DRAFT SCIENTIFIC PROGRAM is now available on-line at www.cpt2004.com

Keep the CPT2004 website - www.cpt2004.com - as one of your favourite bookmarks to ensure you have all the latest Congress news. If you would like any special information in the meantime, please contact:

Congress Secretariat
CPT 2004 C/- ICMS Australasia Pty Ltd
GPO Box 2609, Sydney NSW 2001, Australia
Telephone: (+61 2) 9241 1478
Fax: (+61 2) 9251 3532
Email: enquiries@cpt2004.com
Website: www.cpt2004.com

We look forward to welcoming you to sunny Brisbane, Australia, in August 2004 (1-6 August) – mark these dates in your diary now!

Register at www.cpt2004.com
2004 FASEB Summer Research Conferences

**Saxtons River, Vermont**
- Nucleic Acid Enzymes
- Lymphocytes and Antibodies
- Ubiquitination and Cellular Regulation
- Virus Assembly
- Biological Methylation
- Retinal Neurobiology and Visual Processing
- Lung Surfactant: Cellular and Molecular Biology
- Protein Folding in the Cell
- Mechanisms in Plant Development
- Transcriptional Regulation during Cell Growth, Differentiation and Development

**Tucson, Arizona**
- Microbial Polysaccharides of Medical, Agricultural and Industrial Importance
- Biology of the Calpains in Health and Disease
- Molecular Biophysics of Cellular Membranes
- Post-Transcriptional Control of Gene Expression: Mechanisms of mRNA Decay
- Modern Scientific Approaches to Drug Addiction: Relationships with Behavior
- Protein Lipidation, Signaling and Membrane Domains
- Steroid Hormone Receptors: Integration of Plasma Membrane- and Nuclear-Initiated Signaling in Hormone Action
- Neuro-Immune Interactions: Physiological and Pathological Relevance
- Molecular and Cellular Signaling in the Perinatal Cardiovascular System

**Snowmass Village, Colorado**
- Calcium and Cell Function
- Protein Misfolding, Amyloid and Conformational Diseases
- Transplantation Immunology
- Trace Element Metabolism: Integrating Basic and Applied Research
- Regulation and Biological Function of Small GTPases
- Protein Phosphatases
- Neural Mechanisms in Cardiovascular Regulation
- Folic Acid, Vitamin B12 and One Carbon Metabolism
- Mechanisms of Liver Growth, Development and Disease
- Microbial Pathogenesis: Mechanisms of Infectious Disease

**Pine Mountain, Georgia**
- Thrombospondins and Other Modulatory Adhesion Molecules in Tissue Organization and Homeostasis
- Retinoids
- Advances in Tetraspanin Research
- Renal Microcirculatory and Tubular Dynamics: Molecules to Man
- Yeast Chromosome Structure, Replication and Segregation
- Phospholipases
- Integrative Approaches to Understanding Obesity and its Metabolic and Clinical Consequences
- Antioxidants, Micronutrients, and Phytochemicals in Human Health and Disease

**Mailing List**
To be added to our mailing list, contact:
FASEB Summer Research Conferences
FAX – 301-634-7007
jlevin@faseb.org; ahewitt@faseb.org; mcgovern@faseb.org

**Information & Application**
Available in late March on our web site – http://src.faseb.org

**FASEB Members will Automatically Receive the Meeting Notice**
FASEB SUMMER RESEARCH CONFERENCES

In 1980, FASEB began planning a new program for scientific communication to be at the cutting edge of research in a format entirely different from the annual meeting. The initiation of the FASEB Summer Research Conferences in 1982 spawned a continuing series of interdisciplinary exchanges that have become recognized as a valuable complement to the highly successful Society meetings. The conferences are divided into small groups of experimental biologists who meet intimately and without distractions to explore new approaches to those research areas undergoing rapid scientific change.

Conferences are currently convened in Saxtons River, Vermont; Tucson, Arizona; Snowmass Village, Colorado; and Pine Mountain, Georgia during the months of June, July and August. A scientific advisory committee approves the topics for the conferences. All conferences are scheduled at least two years in advance.

We invite you to submit a proposal for the year 2006 FASEB Summer Research Conferences. To obtain a copy of the guidelines for submitting a proposal, please complete the information requested below and return to the FASEB Summer Research Conferences office.

FASEB SUMMER RESEARCH CONFERENCES
9650 Rockville Pike          Bethesda, MD  20814-3998

E-mail:  jlevin@faseb.org       ahewitt@faseb.org      mcgovern@faseb.org
        http://src.faseb.org

Deadline for submitting proposals for 2006 is Sept. 17, 2004
Definitions of Categories of ASPET Membership

Regular Members: "Any qualified investigator who has conducted and published a meritorious original investigation in pharmacology shall be eligible for membership in the Society." - Bylaws Article II, Section 1, Item 1. An individual who holds an earned doctoral degree (Ph.D., M.D., or equivalent) is considered a qualified investigator. (Exceptions may be made for someone who does not meet the degree requirement but who has made major original research contributions to pharmacology.)

Affiliate Members: "Any qualified person who is engaged in the study of problems in pharmacology but does not meet the requirements for Regular Membership may be eligible for Affiliate Membership, which shall be nonvoting. Affiliate members may later be proposed for Regular Membership, upon meeting the requirements." - Bylaws Article II, Section 1, Item 5. Affiliate Members include representatives in the following careers: faculty members who have made their contribution in teaching; productive research team members who have not published a meritorious original publication; and administrators in government, industry, universities, or other organizations who do not have sufficient independent research to qualify for Regular membership.

Student Members: “Persons who are enrolled in undergraduate, graduate, or professional degree programs, and who have an interest in pharmacology, are eligible for Student membership, which shall be non-voting. Student members may be proposed later for Regular Membership or Affiliate Membership upon meeting the requirements for that membership category. Upon completion of their research doctoral degree, applicants are normally eligible for Regular Membership but may remain in the Student Member category for no more than two (2) years.” - Bylaws Article II, Section 1, Item 6.

- **Regular Members** (Dues $105):
  - Receive *Molecular Interventions* and *The Pharmacologist*.
  - Have free online access to all of ASPET’s journals.
  - May subscribe to print versions of Society publications at reduced member rates.
  - Pay half-price page charge rates ($30/page) and color figure fees ($200/figure) in Society journals.
  - Receive a free copy of the *FASEB Newsletter*.
  - Present independent papers at all Society meetings.
  - Sponsor a paper for a non-member at all Society meetings.
  - Nominate candidates for membership.
  - Vote on all Society ballots and may hold elected office in the Society.
  - Have access to the members only portion of the ASPET Web site (www.aspet.org)
  - Are listed in the FASEB print and on-line directory.

- **Affiliate Members** (Dues $90) have all the benefits of Regular Members except they may:
  - Sponsor candidates for Student membership only.
  - Not sponsor a paper for a non-member at a Society meeting
  - Not vote in Society elections.
  - Not hold an elected office in the Society.

- **Student Members** (Dues $25) have all the benefits of Regular Members except they:
  - Pay no dues their first year.
  - Pay only 25% of the Regular Member dues rate thereafter.
  - Must have their papers at Society meetings sponsored by a member.
  - May not vote in Society elections nor hold an elected office in the Society except for office in the Student Chapter of ASPET.

2004 Publication Subscription Rates for Members

All Society Members qualify for the following reduced publication subscription rates:

- *Journal of Pharmacology and Experimental Therapeutics* (Monthly) - $156/year
- *Pharmacological Reviews* (Quarterly) - $66/year
- *Drug Metabolism and Disposition* (Monthly) - $78/year
- *Molecular Pharmacology* (Monthly) - $102/year
- *Clinical Pharmacology and Therapeutics* (Monthly) - $38/year, $70/year for Canada/Foreign
- *Molecular Interventions* (Bimonthly) – included with dues

Application Instructions and Suggestions

Submit a typed original and one (1) copy of the completed Application for Membership form or use the online application form on the ASPET web site at [http://www.aspet.org/membership](http://www.aspet.org/membership). Submit a current curriculum vitae including bibliography for Regular and Affiliate Membership. You may e-mail the CV.

Sponsor Statements

Submit signed statement(s) of qualifications of the applicant from two Regular Members of ASPET for Regular Membership and from one Regular Member of ASPET for Affiliate Membership and Student Membership (Affiliate Members may also sponsor student applicants). In addition to statement certifying that the applicant is qualified for ASPET membership, sponsors please provide your own current address, phone, fax and email. **It is the responsibility of the applicant to secure these documents.**
Application for Membership
American Society for Pharmacology and Experimental Therapeutics
9650 Rockville Pike, Bethesda, Maryland 20814-3995 USA, Phone (301) 634-7060
Application for ( ) Regular, ( ) Affiliate, ( ) Graduate Student, or ( ) Undergraduate Student Membership
Year: ( ) Fresh, ( ) Soph, ( ) Jr, ( ) Sr

APPLICANT. Please complete this section – type if possible.

Name and Address: Telephone:

FAX:

E-mail:

Date of Birth:

Education and Training:

Professional Experience (Present position first) Include dates, position and organization.

Paperwork Summary: submit original and 1 copy of the following:

1. Application form.

2. Statement and signatures from two sponsors for Regular membership and from one sponsor for Affiliate/Student membership.*

3. Curriculum vitae (include bibliography) for Regular and Affiliate membership.

*A letter or e-mail may be sent by the sponsor to the Membership Coordinator (rphipps@aspet.org) in lieu of the sponsor's signature and statement of qualifications of the applicant on the form. Call or e-mail the ASPET Membership Department for additional information: (301) 634-7135 / rphipps@aspet.org

For on-line submission, go to http://www.aspet.org/public/membership/memberappform_ia_1003.pdf
Future Meetings

Experimental Biology ‘04
Washington, DC
Saturday-Wednesday
April 17-21, 2004
(AAA, AAI, APS, ASIP, ASNS, ASPET)

Pharmacotherapy of
Obesity: Targets & Tools
for the 21st Century
ASPET-Ray Fuller Symposium
Washington, DC
Friday, April 16, 2004

2nd RGS Protein
Colloquium
Washington, DC
Saturday, April 17, 2004

4th International Symposium
of Nucleosides and Nucleo-
tides (Purines 2004)
Chapel Hill, NC
June 6-9, 2004